National guidelines for the management of absolute cardiovascular disease risk

Med J Aust. 2014 May 5;200(8):454, 456. doi: 10.5694/mja13.11162.

Authors

Christopher J O'Callaghan¹, Pei Rong², Min Y Goh²

Affiliations

¹ Austin Health, Melbourne, VIC, Australia. Christopher.ocallaghan@austin.org.au.
² Austin Health, Melbourne, VIC, Australia.

PMID: 24794600
DOI: 10.5694/mja13.11162

No abstract available

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Australia
Cardiovascular Diseases / drug therapy*
Cardiovascular Diseases / prevention & control
Disease Management
Drug Therapy, Combination
Humans
Hypertension / drug therapy*
Practice Guidelines as Topic
Risk Factors

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors